Sign In
Buy MTNB
$0.778
+0.0120 (+1.57%)
At Close: Jun 03, 2026
Two Sigma Advisers LP Takes Position in Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB)
10:52pm, Wednesday, 15'th Jul 2020
Two Sigma Advisers LP bought a new stake in Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) during the first quarter, according to the company in its most recent disclosure with the Securities and
3 Healthcare Stocks Under $5 With Triple-Digit Upside Potential
07:30pm, Tuesday, 14'th Jul 2020
On Wall Street, some things never change. Public health crisis or not, the fact of the matter remains that healthcare stocks are the epitome of risk/reward plays. Why? It comes down to the nature of t
State Street Corp Increases Stock Holdings in Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB)
04:02am, Sunday, 05'th Jul 2020
State Street Corp boosted its position in shares of Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) by 658.7% in the first quarter, according to its most recent filing with the Securities and Excha
The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes
12:12pm, Wednesday, 01'st Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) * ADC Therapeutics SA (NYSE: ADCT) * Akebia Therapeu
The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes
12:00am, Wednesday, 01'st Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 30)
ADC Therapeutics SA (NYSE:...
Matinas BioPharma Resumes Enrollment in the ENHANCE-IT and EnACT Clinical Trials
08:15pm, Tuesday, 30'th Jun 2020
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has commenced enrollment and started dosing patients in the ENHANCE-IT study and that it expects to resume dosing patients i
Matinas BioPharma (NYSEAMERICAN:MTNB) Shares Gap Up to $0.89
06:39am, Friday, 26'th Jun 2020
Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) gapped up prior to trading on Wednesday . The stock had previously closed at $0.95, but opened at $0.89. Matinas BioPharma shares last traded at $0.8
Hedge Funds Have Never Been This Bullish On Matinas Biopharma Holdings, Inc. (MTNB)
01:15am, Wednesday, 24'th Jun 2020
In this article we will take a look at whether hedge funds think Matinas Biopharma Holdings, Inc. (NYSE:MTNB) is a good investment right now. We check hedge fund and billionaire investor sentiment bef
Matinas BioPharma to Present at the Jefferies Virtual Healthcare Conference
11:00am, Tuesday, 26'th May 2020
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a company overview during the Jefferies Virtual Healthc
Whilst it may not be a huge deal, we thought it was good to see that the Matinas BioPharma Holdings, Inc...
Will Matinas BioPharma Continue to Surge Higher?
02:59pm, Monday, 18'th May 2020
As of late, it has definitely been a great time to be an investor of Matinas BioPharma
Edited Transcript of MTNB earnings conference call or presentation 11-May-20 8:30pm GMT
07:48am, Tuesday, 12'th May 2020
Q1 2020 Matinas BioPharma Holdings Inc Earnings Call
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q1 2020 Results - Earnings Call Transcript
02:45am, Tuesday, 12'th May 2020
Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Peter Vozzo - Investor Relations J
Matinas Biopharma Holdings Inc (MTNB) Reports Q1 Loss, Misses Revenue Estimates
11:45pm, Monday, 11'th May 2020
Matinas Biopharma Holdings Inc (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for t
Matinas BioPharma Reports First Quarter 2020 Financial Results and Operational Highlights
08:05pm, Monday, 11'th May 2020
– ENHANCE-IT study of MAT9001 against Vascepa® set to resume in June 2020 – – EnACT study of MAT2203 in cryptococcal meningitis expected to resume in June 2020 – – Management.
